🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 19 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 28/05/2002 | 19,75 | 20,79 | 19,22 | 20,64 | +5,68% | 7,95% | 680.800 |
| 24/05/2002 | 21,40 | 21,43 | 19,48 | 19,53 | -8,95% | 9,11% | 908.300 |
| 23/05/2002 | 19,20 | 21,79 | 18,75 | 21,45 | +13,37% | 15,83% | 1.040.000 |
| 22/05/2002 | 17,95 | 19,16 | 17,92 | 18,92 | +2,83% | 6,91% | 579.500 |
| 21/05/2002 | 18,81 | 19,30 | 18,11 | 18,40 | -0,81% | 6,33% | 1.010.000 |
| 20/05/2002 | 19,30 | 19,39 | 18,45 | 18,55 | -4,92% | 4,87% | 450.800 |
| 17/05/2002 | 18,40 | 19,75 | 18,14 | 19,51 | +5,29% | 8,75% | 832.900 |
| 16/05/2002 | 19,51 | 19,70 | 18,53 | 18,53 | -4,88% | 6,00% | 671.400 |
| 15/05/2002 | 19,40 | 20,09 | 18,79 | 19,48 | -0,46% | 6,70% | 728.100 |
| 14/05/2002 | 18,71 | 19,71 | 18,70 | 19,57 | +6,47% | 5,40% | 902.400 |
| 13/05/2002 | 17,29 | 18,38 | 17,16 | 18,38 | +7,23% | 7,06% | 1.059.400 |
| 10/05/2002 | 17,60 | 17,75 | 16,80 | 17,14 | -0,52% | 5,40% | 791.300 |
| 09/05/2002 | 18,55 | 19,18 | 17,23 | 17,23 | -8,79% | 10,51% | 790.100 |
| 08/05/2002 | 17,42 | 18,90 | 17,15 | 18,89 | +11,84% | 10,05% | 1.247.100 |
| 07/05/2002 | 17,10 | 17,29 | 16,00 | 16,89 | -0,65% | 7,54% | 1.102.300 |
| 06/05/2002 | 17,80 | 18,35 | 16,75 | 17,00 | -6,54% | 8,99% | 1.068.300 |
| 03/05/2002 | 19,15 | 19,15 | 17,85 | 18,19 | -5,36% | 6,79% | 1.556.000 |
| 02/05/2002 | 20,70 | 20,71 | 19,01 | 19,22 | -7,37% | 8,21% | 989.300 |
| 01/05/2002 | 21,08 | 21,25 | 19,78 | 20,75 | -2,44% | 6,97% | 769.600 |
| 30/04/2002 | 19,80 | 21,39 | 19,52 | 21,27 | +5,82% | 9,44% | 984.500 |
| 29/04/2002 | 19,25 | 20,72 | 19,24 | 20,10 | -0,59% | 7,69% | 889.400 |
| 26/04/2002 | 21,40 | 21,47 | 19,85 | 20,22 | -1,37% | 7,57% | 1.194.900 |
| 25/04/2002 | 22,29 | 22,30 | 19,70 | 20,50 | -12,43% | 11,66% | 3.606.700 |
| 24/04/2002 | 28,20 | 28,20 | 22,95 | 23,41 | -18,60% | 18,62% | 5.606.000 |
| 23/04/2002 | 30,29 | 30,95 | 28,59 | 28,76 | -4,17% | 7,79% | 921.000 |
| 22/04/2002 | 31,50 | 31,60 | 29,50 | 30,01 | -5,06% | 6,67% | 988.800 |
| 19/04/2002 | 32,40 | 32,45 | 30,97 | 31,61 | +2,17% | 4,57% | 1.627.300 |
| 18/04/2002 | 30,41 | 30,98 | 30,23 | 30,94 | +1,78% | 2,47% | 1.261.600 |
| 17/04/2002 | 30,44 | 30,95 | 30,12 | 30,40 | -0,10% | 2,73% | 820.600 |
| 16/04/2002 | 30,94 | 31,94 | 29,82 | 30,43 | -1,27% | 6,85% | 1.403.000 |